Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: psoriatic arthritis

Guselkumab Promising for Psoriatic Arthritis with Axial Symptoms

Lorraine L. Janeczko  |  July 17, 2021

NEW YORK (Reuters Health)—Guselkumab may be effective in patients who have psoriatic arthritis (PsA) with axial symptoms, a post-hoc analysis of data from two randomized controlled trials suggests.1 “Because PsA is a heterogeneous disease that manifests as various symptoms, treatment choices should involve consideration of all relevant domains of disease for each individual patient,” researchers…

Filed under:ConditionsDrug UpdatesPsoriatic Arthritis Tagged with:Drug UpdatesguselkumabPsoriatic Arthritis

Guselkumab Promising to Slow Joint Damage in Patients with Psoriatic Arthritis

Michele B. Kaufman, PharmD, BCGP  |  June 29, 2021

In an efficacy and safety study of guselkumab, patients with active psoriatic arthritis taking guselkumab showed continued skin clearance and joint symptom relief, as well as statistically significant inhibition of joint damage, after two years.

Filed under:ConditionsDrug UpdatesPsoriatic Arthritis Tagged with:Psoriatic Arthritis

Outcome Assessments: Measuring Global Disease Activity in Patients with Psoriatic Arthritis

Jason Liebowitz, MD, FACR  |  June 23, 2021

Laura Coates, MBChB, MRCP, PhD, described & compared the intricacies of different outcome measures, as well as implications for clinical practice & trials, for patients with psoriatic arthritis.

Filed under:ConditionsEULAR/OtherMeeting ReportsPsoriatic Arthritis Tagged with:EULARoutcomeOutcome measuresPsoriatic Arthritis

Secukinumab Effective Across the Spectrum of Psoriatic Arthritis

Mary Beth Nierengarten  |  April 5, 2021

A posthoc analysis confirms patients with active psoriatic arthritis (PsA) taking secukinumab experience improvement in all signs and symptoms of PsA as measured by the GRAPPA-OMERACT disease activity core domains.

Filed under:Biologics/DMARDsConditionsDrug UpdatesPsoriatic Arthritis Tagged with:GRAPPA-OMERACTPsoriatic Arthritissecukinumab

kenary820 / shutterstock.com

Psoriatic Arthritis FocusRheum

Psoriatic arthritis (PsA) is distinguished from other forms of inflammatory arthritis by unique pathophysiology and manifestations. In this resource center, you’ll find Dr. David’s Pisetsky’s picks for the top research in psoriatic arthritis presented at ACR Convergence 2024 and our summary of the most recent ACR treatment guideline, as well as a collection of important…

Cytokine Targets & Treatment Developments for Psoriatic Arthritis & Spondyloarthritis

Carina Stanton  |  March 15, 2021

ACR CONVERGENCE 2020—In recent years, a pathophysiological role for the interleukin (IL) 17/IL-23 axis in the development of psoriasis, enthesitis and inflammatory arthritis has been investigated in both rodent and human models. Clinical trials have demonstrated differential benefits for skin disease and joint disease in patients with psoriatic arthritis, axial spondyloarthritis (axSpA) and ankylosing spondylitis…

Filed under:Axial SpondyloarthritisConditionsPsoriatic Arthritis Tagged with:ACR Convergence 2020Ankylosing SpondylitisIL-17/IL-23 CytokineJanus Kinase InhibitorsPsoriatic Arthritis

European Commission Approves Upadacitinib for Psoriatic Arthritis & Ankylosing Spondylitis

Michele B. Kaufman, PharmD, BCGP  |  February 4, 2021

In January, upadacitinib was approved for use in Europe as a 15 mg, once-daily dose to treat patients with psoriatic arthritis and ankylosing spondylitis.

Filed under:ConditionsDrug UpdatesPsoriatic Arthritis Tagged with:Ankylosing SpondylitisEuropean UnionPsoriatic Arthritisupadacitinib

Study Shows Psoriatic Arthritis Impacts Women More Than Men

Mary Beth Nierengarten  |  January 19, 2021

Psoriatic arthritis (PsA) has a higher life impact on women than men, suggesting the need to include life impact as part of the treat-to-target strategy for PsA. This is the finding of a recently published study by Orbai et al., which found female sex independently linked to high PsA life impact.1  The Study The study…

Filed under:ConditionsPsoriatic ArthritisResearch Rheum Tagged with:Disparitieshealth disparitieslife impactPsoriatic Arthritissex disparitiesTreat-to-Target

FDA Approves Golimumab for Patients with pJIA & Psoriatic Arthritis

Michele B. Kaufman, PharmD, BCGP  |  October 21, 2020

The FDA has approved golimumab for the treatment of pediatric patients with active polyarticular juvenile idiopathic arthritis or active psoriatic arthritis…

Filed under:Biologics/DMARDsConditionsDrug UpdatesPediatric Conditions Tagged with:FDA approvalGolimumabPediatricpolyarticular juvenile idiopathic arthritispolyarticular juvenile idiopathic arthritis (JIA)Psoriatic ArthritisU.S. Food and Drug Administration (FDA)

FDA Approves Tremfya (Guselkumab) for Adult Patients with Psoriatic Arthritis

Natasha Yetman  |  July 15, 2020

HORSHAM, PA—The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterized by painful joints and skin inflammation.1,2 Tremfya is the first treatment approved for active PsA that selectively inhibits interleukin (IL)…

Filed under:Biologics/DMARDsDrug Updates Tagged with:FDA approvalguselkumabU.S. Food and Drug Administration (FDA)

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 63
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences